AOD-9604 for Fat Loss: Protocol, Dosing, and What to Expect

What this protocol is for

AOD-9604 is a fragment of growth hormone (the 176-191 amino acid sequence) isolated for its lipolytic effects without the rest of the GH molecule's anabolic and metabolic signaling. Mechanism: it stimulates fat oxidation in adipose tissue without elevating IGF-1, increasing insulin resistance, or driving the broader GH cascade. The case for AOD is precision: a tool that does one thing (mobilise stored fat) and stays out of the way of everything else.

The clinical pattern in user reports is consistent. Men running a cutting block who want lipolysis support without the broader effects of full GH peptides. Lean-ish users dealing with stubborn body fat that does not respond to diet and training alone. Athletes managing body composition for sport-specific goals where IGF-1 elevation would be unwelcome. Anecdotally, users report modest but real fat-loss acceleration over 8 to 12 weeks on top of an active deficit; the effect is smaller than GLP-1 analogs deliver but the side-effect profile is cleaner.

Used by many in the recovery / biohacking space as the targeted fat-loss layer in a cutting protocol, often stacked with CJC-1295 and Ipamorelin for combined GH-pathway support. Run this as a tactical, legal performance layer on top of the diet and training work that creates the deficit. AOD does not suppress appetite, alter glucose metabolism, or create the deficit. It supports the lipolytic side of an existing deficit.

Dose for fat loss

300 mcg subcutaneous once daily, typically morning on an empty stomach (fasted state amplifies lipolytic signaling). Some protocols dose pre-training instead to align the lipolytic pulse with the exercise-driven fat oxidation window. Abdominal subcutaneous is the standard route.

Cycle length

8 to 12 weeks aligned with a structured calorie deficit and training block. AOD without a paired deficit does not produce fat loss. Cycle off 4 to 6 weeks before another run.

Stack pairings

Commonly stacked with CJC-1295 and Ipamorelin.

Expected timeline

Week 1–3: minimal subjective change; the lipolytic signal builds slowly. Week 4–8: body composition shifts become visible alongside the calorie deficit. Most users report stubborn body fat areas (lower abdominal, lower back) start moving in this window where they had previously plateaued. Week 8–12: cumulative fat-loss acceleration lands. Scale weight drops 1 to 2 kg beyond what diet alone would have delivered in the same window.

Common mistakes

• Running AOD without a calorie deficit. The peptide supports lipolysis; lipolysis only delivers fat loss when energy demand exceeds intake. Without the deficit, the protocol is wasted.
• Expecting GLP-1-level results. AOD is a precision lipolysis tool, not an appetite or metabolic intervention. The effect is modest acceleration on top of an existing deficit, not standalone fat loss.
• Dosing AOD with food. Lipolytic signaling is more pronounced in a fasted state. Morning fasted dosing or pre-training dosing on light stomach is the standard rhythm.
• Stacking AOD with high-dose CJC and high-dose insulin-affecting protocols simultaneously. The peptide pathways stack cleanly but the broader metabolic management gets complex. Keep the protocol simple unless under clinical supervision.
• Cycling shorter than 8 weeks. AOD is back-loaded; the visible body composition effects land in the second half of the cycle.